Organon OGN Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number at other companies

ViatrisVTRS

——

Merck & Co.MRK

——

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Market cap$3.53B-59.4%

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Organon's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?: Organon (OGN) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number of $5.77M in Q1 2026.
How has Organon's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number changed year-over-year?: Organon's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number decreased by 35.8% year-over-year, from $8.98M to $5.77M.